Xencor, Inc. develops engineered antibody therapeutics for cancer and autoimmune diseases using its XmAb technology platform and related antibody-engineering formats. News about XNCR commonly covers clinical and preclinical updates for XmAb drug candidates, including TL1A programs such as XmAb942 and XmAb412, T-cell engaging bispecific antibodies such as XmAb819 and XmAb541, and presentations of data at medical meetings.
Recurring company updates also include quarterly financial results, research-and-development priorities, collaboration and licensing activity, intellectual-property developments tied to Xtend Fc domain technology, and royalty matters involving partner-marketed medicines such as Ultomiris.
Xencor, Inc. (NASDAQ:XNCR) presented initial data from the Phase 2 study of vudalimab, a bispecific antibody, targeting metastatic castration-resistant prostate cancer (mCRPC) at the Society for Immunotherapy of Cancer Annual Meeting in Boston. The study included nine patients, with three showing more than 50% PSA reductions. However, safety concerns led to a reduction in chemotherapy intensity for future cohorts. Xencor plans to explore alternative chemotherapy combinations and has multiple ongoing studies for vudalimab and other XmAb programs.
Xencor, Inc. (NASDAQ:XNCR) reported Q3 2022 results, showing $27.3 million in revenue, up from $19.7 million in Q3 2021. The net loss decreased to $32.8 million or $(0.55) per share, compared to $(0.69) in Q3 2021. Key highlights include promising results from the XmAb564 IL-2 cytokine study, demonstrating a 117-fold Treg expansion. Xencor anticipates ending 2022 with $575 million to $600 million in cash and expects to fund R&D through 2025. Additional updates on clinical programs are forthcoming.
Xencor announced positive topline results from the Phase 1a study of XmAb564, a novel therapy targeting regulatory T cells (Tregs) for autoimmune diseases. A 117-fold increase in CD25bright Tregs was observed at the highest dose, with sustained activity over three weeks. XmAb564 was well-tolerated, showing no serious adverse events, and the first patient has been dosed in a Phase 1b study for atopic dermatitis and psoriasis. Results will be discussed in a webcast today at 4:30 PM ET.
Xencor, Inc. (NASDAQ: XNCR) announced it will present clinical data from its Phase 1 study of plamotamab, a CD20 x CD3 bispecific antibody, at the ASH Annual Meeting on December 12, 2022. Plamotamab showed encouraging results in patients with relapsed non-Hodgkin’s lymphoma. The study indicated a 47.4% overall response rate (ORR) in patients with diffuse large B-cell lymphoma and a 100% ORR in those with follicular lymphoma. Despite common adverse events like cytokine release syndrome, the treatment was generally well tolerated. This marks a significant step in Xencor's development of targeted cancer therapies.
Xencor, Inc. (NASDAQ: XNCR) announced it will release its third quarter 2022 financial results on November 7, 2022, after market close. A conference call and webcast will follow at 4:30 p.m. ET to discuss the results and provide an update on corporate activities. Xencor is engaged in developing engineered antibodies and cytokines to treat cancer and autoimmune diseases, with over 20 candidates in clinical trials and three marketed medicines utilizing its XmAb® technology.
SpikImm's SPK001, a monoclonal antibody for COVID-19 prevention, has been awarded "national priority" status by the French government. In Phase 1 trials, it showed excellent tolerance among initial cohorts. Targeting immunocompromised patients, the drug could address a significant market need, with around 300,000 patients in France alone. SpikImm plans to advance to a Phase 2 trial by Q1 2023 and may seek early access approval in Q2 2023. The company has partnered with Xencor to enhance the antibody's efficacy.
Xencor, Inc. (NASDAQ:XNCR) announced seven poster presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer from November 10-12, 2022, in Boston. Key highlights include data from a Phase 2 study of vudalimab, a PD-1 x CTLA-4 bispecific antibody, plus chemotherapy for metastatic castration-resistant prostate cancer (mCRPC). Other studies involve XmAb819 for renal cell carcinoma and various preclinical programs. The findings will enhance understanding of these treatments and their potential impact on cancer therapies.
Xencor, Inc. (NASDAQ:XNCR) announced the appointment of Dr. Nancy Valente to its board of directors, bringing over 20 years of experience in late-stage biopharmaceutical development, particularly in oncology. Dr. Valente previously held a senior position at Genentech, where she played a critical role in the launch of several therapies. Concurrently, Yujiro S. Hata, a director since 2015, resigned from the board. The leadership change is expected to enhance Xencor's strategic direction as it continues developing engineered antibodies for cancer and autoimmune diseases.
Xencor, Inc. reported its financial results for Q2 2022, with total revenue of $30.2 million, down from $67.4 million in Q2 2021. The company recognized $22.1 million in royalties from Vir Biotechnology and $6.7 million from Alexion Pharmaceuticals. R&D expenses declined to $47.1 million from $49.5 million year-over-year, while G&A expenses increased to $11.1 million. Xencor posted a net loss of $34 million, or $(0.57) per share, compared to a net income of $52.2 million, or $0.87 per share, in Q2 2021. The company anticipates having sufficient cash to fund operations through 2025.
On August 2, 2022, Caris Life Sciences and Xencor, Inc. (NASDAQ: XNCR) announced a strategic agreement to develop XmAb® bispecific antibodies targeting novel cancer treatment options. Caris will utilize its proprietary discovery platform to identify these targets, while Xencor will leverage its XmAb engineering technology. Xencor will receive exclusive options to commercialize products related to three targets, alongside a payment of up to $120 million in milestones and royalties. This collaboration aims to address the need for new therapeutic targets in oncology.